Wolfe Research Downgrades RAPT Therapeutics to Peer Perform
Portfolio Pulse from Benzinga Newsdesk
Wolfe Research analyst Andy Chen downgraded RAPT Therapeutics (NASDAQ:RAPT) from Outperform to Peer Perform, indicating a change in the firm's outlook on the stock.

May 14, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Wolfe Research's downgrade of RAPT Therapeutics from Outperform to Peer Perform suggests a neutral outlook on the stock, potentially impacting investor sentiment.
Analyst ratings can significantly influence investor sentiment and stock prices. A downgrade to Peer Perform implies that Wolfe Research sees RAPT Therapeutics as performing in line with its peers, rather than outperforming them. This could lead to a neutral short-term impact on the stock as investors reassess their expectations based on this new rating.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100